Raphaël Gaillard, Olivier Mir. Show Affiliations »
Abstract
Entities: Chemical Disease
Mesh： See more » AnimalsAryl Hydrocarbon Hydroxylases/antagonists & inhibitorsBrain Ischemia/drug therapyBrain Ischemia/physiopathologyBrain Ischemia/rehabilitationClopidogrelCytochrome P-450 CYP2C19Drug ResistanceFluoxetine/pharmacologyFluoxetine/therapeutic useHumansMotor Skills/drug effectsMotor Skills/physiologyPlatelet Aggregation Inhibitors/therapeutic useRecovery of FunctionSerotonin Uptake Inhibitors/pharmacologySerotonin Uptake Inhibitors/therapeutic useStroke/drug therapyStroke/physiopathologyStroke RehabilitationTiclopidine/analogs & derivativesTiclopidine/therapeutic useTreatment OutcomeVascular Endothelial Growth Factor A/metabolism
Substances： See more » Platelet Aggregation InhibitorsSerotonin Uptake InhibitorsVascular Endothelial Growth Factor AFluoxetineClopidogrelAryl Hydrocarbon HydroxylasesCYP2C19 protein, humanCytochrome P-450 CYP2C19Ticlopidine
Year: 2011 PMID： 21601157 DOI： 10.1016/S1474-4422(11)70111-9
Source DB: PubMed Journal: Lancet Neurol ISSN： 1474-4422 Impact factor: 44.182